CD8A and neoplasm: In a preclinical study, combination of GVAX with TGF-β inhibitors enhanced TLS formation, CD8+ T cells infiltration, and intra-tumor Treg depletion in pancreatic tumor-bearing mice, resulting in an improved anti-tumor effect of the vaccination (94).